Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
it is probably a fat finger stupidity
I have to wonder the expanded benefit of DCVax-L with the clinical constraints not there, when being used in a normal cancer therapy environment. The volumes of patients who could saved from an early death sentence with SOC now in place. To have that option and the mental readjustment helping, in contrast to the lack of hope given by current SOC.
DCVax-direct may be given a huge boost in clinical due to DCVax-L successes.
Murder is a normal practice of murderers
This could be the updated presentation that sets the GBM therapy world a fire & DCVax-L Speculation will be put to rest .
Except there is zero reason to sell.
I thank everyone. God bless all.
One would think such notable research by these prestigious professionals & scientist would be enough to cause more of a positive involvement by even the most conservative investment institution.
There are 7 cases of cancer in my family with 3 of them being brain cancers and 2 of the cases resulting in death so far. I was drawn to this investment be virtue of therapies and research and then, investment.
Yes, the exposure in the conference is a great point.
I was thinking about the news release reference last week regarding Sept as a guidance target and now this presentation . Surprises abound and a presentation with more revelations could be pretty amazing for future guidance. I’ve been invested here for a couple yrs and accumulating with all considered a long hold. The movement up through the .30s is very welcomed & more news could change the face of NWBO in the institutional investment community.
Your insight is more informed than mine.
ATL. How do you think the presentation works out in relation to DL
ATLnsider @ATLnsider · 8h $NWBO #DCVAX news: Northwest Biotherapeutics CEO, Linda Powers will present DCVax® Personalized Immune Therapies on 9/12/20 at the American Brain Tumor Association (ABTA) virtual 2020 National Conference (see pg. 6): DCVax® Personalized Immune Therapies: https://abta.org/wp-content/uploads/2020/09/2020-National-Conference-VIRTUAL-Program-Final_9.1.2020.pdf
Northwest Biotherapeutics
DCVax® Personalized Immune Therapies: Explanation of what dendritic cell therapies (such as DCVax) are, how they work and how they are different from other kinds of treatments for Glioblastoma
Ms. Linda Powers, CEO
ATLnsider
@ATLnsider
·
8h
$NWBO #DCVAX news: Northwest Biotherapeutics CEO, Linda Powers will present DCVax® Personalized Immune Therapies on 9/12/20 at the American Brain Tumor Association (ABTA) virtual 2020 National Conference (see pg. 6): DCVax® Personalized Immune Therapies: https://abta.org/wp-content/uploads/2020/09/2020-National-Conference-VIRTUAL-Program-Final_9.1.2020.pdf
An unlimited amount of naked shorts dropped it from $12 to pennies. NWBO should have never dropped below $5 and wouldn’t have on its own. The drop was like tripping someone walking down the stairs and saying they fell on their own. There would have been less shares issued, if the sp was above $5 over the last few years and the shorts are to blame, no one else.
Per the news release, for someone concerned with reading and understanding.
The acquisition includes both intellectual property owned by Flaskworks and a license of additional intellectual property from Northeastern University.
The question is, how much is the end reduction in DCVax-L cost of production, return on that investment & opportunity for generating revenue as a production service for other customers?
Because of so much false info, here is the last real info from Northwest Bio Announces Completion of Further Data Gathering For Phase III Trial
BETHESDA, Md., August 19, 2020 - Northwest Biotherapeutics (OTCQB: NWBO)(“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the remaining outstanding clinical trial data for the Company’s Phase 3 trial of DCVax®-L for Glioblastoma brain cancer as described in the Company’s last report on July 24, 2020 has now been completed by the specialty analytics firms. With this data now in hand, final quality control checking and confirmation are under way to enable Data Lock.
This further data involves specialty analytics such as genomic profiling for IDH mutations and certain imaging. The independent CRO managing the trial is now integrating this data into the overall trial database containing the clinical data from the trial sites that was already complete and locked as reported on July 24, 2020, in order to complete the overall trial dataset.
When Data Lock is reached, the independent statisticians will be given access to the unblinded dataset. The Company will remain blinded while the statisticians make the computations, converting the mass of raw data from the trial into formal tables and listings, and survival and progression measures, to report the trial results.
As previously reported, the statisticians’ work is estimated to take a couple of weeks. When their computations are completed, the Company will receive the results of those computations and thereby become unblinded. It is anticipated that the Company’s Scientific Advisory Board, the Steering Committee of the Trial and other key medical expert advisors will likewise receive the results, and thereby become unblinded as well.
The Company currently continues to anticipate reporting topline trial data in September, and anticipates providing further updates as the process progresses.
no quotes right now for me
https://www.medicalnewstoday.com/articles/317295. glioblastoma and sugar
Very interesting and informative. Thank you for posting, as this narrows down data release. It will be an interesting next few months as the results are digested by real scientist with significant understanding.
mommy are we there yet.
If NWBO doesn’t have data lock before EOY I’m good with that , but it will happen when it happens. The complaining sounds like a bunch of children asking “are we there yet”. Why don’t the complainers go buy a couple hundred thousand shares of something like Merck and just kick back and relax.
CNN Communist News Network working to destroy the world
Mgt could have requested the Fairy God Mother to give them $100 million , but that money seems to be reserved for other things, so nwbo sold stock instead. Why don’t all of you that hate the dilution just send them a few million$ for free.
Biotech development takes money and without a revenue source,they rely on stock to pay for the research. This is how it us in the real world,we pay for things like research and employees.
So many seem to not understand there is a difference between clinical use of a therapy and application of therapy in the real patient world of everyday treatment.
His last breath here , will be his first breath in heaven where no pain is felt. God Bless
On August 14, 2020, Northwest Biotherapeutics, Inc. (the “Company”) entered into a Note Purchase Agreement and Note (collectively, the “Note”) with Iliad Research and Trading, L.P. (the “Holder”) in the amount of $5,505,000. The Note has a maturity of 21 months. There are no repayments during the first 7 months of the term. During months 8 through 21, the Note will be amortized in monthly installments of 110% of the pro rata principal amount. Interest on the Note accrues at a rate of 8% per annum, and the Note includes an original issue discount of $500,000.
My opinion , the impedes for a $1 or $2 sp will cause and institutional investment taking NWBO to $6 & higher and triggering even more interest as it solidly passes $5 .
I’m amazed the FDA doesn’t step in, take a look at early data and give Accelerated Approval pending full analysis, given the qualifications of gbm as a potential death sentence and the successes of DCVax-L . I would love to see one of the other FDA equivalent agencies being filed in, give their approval before FDA.
That is a glorious moment for her father to have a chance at life with DCVax-L and to realize it is so successful , is a blessing. God bless him.
God Bless
Is there a suggestion of AA or something else?
History of Changes for Study: NCT03014804
Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma
https://clinicaltrials.gov/ct2/history/NCT03014804?A=13&B=14&C=Side-by-Side#StudyPageTop
Actually Bigger just added 500,000 shares last week. He posted that on twitter last week.
A first year med student would know intentionally putting an infected patient in with the most vulnerable population described by the medical community, would lead to disproportionate death in that population. Those directives were signed into effect and implemented by knowledgable people. It was not an accident to put them in with elderly, it was done by decree. Hospitals didn’t want potentially infected patients in waiting rooms, why would you place known infected in with elderly identified as the most vulnerable?
This is way off topic for this board.
The cumulative financial and supply chain interruption is going to be more devastating as we go along . This shutdown is truly worse than any virus. The deaths of many elderly was intentional and avoidable in my view. Sending covid + patients back into facilities filled with the most vulnerable, was criminal.
https://www.macrotrends.net/countries/USA/united-states/death-rate
8.8 per 1000 die of something each year in the USA. Life goes on and we don’t miss a beat. Supposedly 1 per 1800 die of covid and we shut down businesses, livelihoods, travel and destroy the economy. I see no logic in the rational.
I’ll be glad when all the data is quantified, qualified and all our conjecture is put to rest by facts. It has been a long road, with an amazing collective of very wise people trying to fill all the voids with summations of known data. That is why I invest in biotech though. The rewards are quite high when all is said and done with an approval and highly marketable asset . It also
forces one to read and be exposed to aspects of medical knowledge one wouldn’t normally become aware. It isn’t like owning P&G or GE stock.